Percheron Therapeutics Limited · ASX:PER
Percheron Therapeutics — Shareholder Meeting (October 2026)
13 slides from Percheron Therapeutics's shareholder meeting presentation, Oct 7, 2026
Slide 1: Chair's Address to the AGM
For personal use only ASX Announcement CHAIR’S ADDRESS TO THE AGM Melbourne, Australia – 7 October 2026: In advance of this morning’s Annual General Meeting of shareholders to be held at 10:00am, and in accordance with ASX Listing Rule 3.13.3, Percheron Therapeutics Limited (ASX: PER or ‘the Company
Slide 2: Chair's Opening Address to the Meeting
PERCHERON THERAPEUTICS LIMITED (ABN 41 095 060 745) ANNUAL GENERAL MEETING OF SHAREHOLDERS For personal use only 7 October 2026 CHAIR’S OPENING ADDRESS TO THE MEETING Ladies and Gentlemen, I am very pleased to welcome you, on behalf of the Board of Directors, to the 2026 Annual General Meeting for P
Slide 3: Chair's address (continued)
work that was recently presented at the prestigious ASCO conference earlier this year in June. The research demonstrated VISTA is upregulated in patients with triple negative breast cancer, resistant to chemotherapy and the marker is over expressed in women For personal use only after treatment with
Slide 4: Chair's address: CEO introduction and thanks
You will shortly hear from Dr Michael Baker, who despite only becoming CEO of the company two days ago, has already given much thought to our road ahead. I and the other directors are delighted to have him on board, and we look forward to working with For personal use only him. Michael brings a weal
Slide 5: Becoming a Clinical-Stage Oncology Company: Annual General Meeting
Becoming a Clinical-Stage rsonal use only Oncology Company Presentation to Annual General Meeting Dr Charmaine Gittleson | Chair of the Board of Directors 7 October 2026 ASX: PER US OTC: PERCF WWW.PERCHERONTX.COM
Slide 6: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions such as the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such
Slide 7: Substantial progress with HMBD-002, ready to commence a new clinical trial
Percheron has made substantial progress with HMBD-002, and now stands ready to commence a new clinical trial JUN 2025 AUG 2025 OCT 2025 APR 2026 JUN 2026 AUG 2026 rsonal use only Percheron licenses Researchers at Percheron Phase I trial data Percheron Dr Michael Baker HMBD-002, a best- UTSW publish
Slide 8: Progressive de-risking of the HMBD-002 program for investors
The achievements of the past 12-15 months can be thought of as progressive de-risking of the HMBD-002 program for investors rsonal use only Safety Manufacturability Efficacy Commerciality Is the drug Can it reliably Will clinicians Does it work? safe? be made? prescribe it? Third batch of drug Stron
Slide 9: Investigator-sponsored studies provide an efficient way to move the program forward
Investigator-sponsored studies, such as the recently announced Vanderbilt collaboration, provide a highly efficient way to move the program forward 70-80% cost savings rsonal use only compared to typical cost of a company-sponsored trial Independent third-party validation of the program clinicians d
Slide 10: Immune checkpoint inhibitors: close to US$50 billion in annual sales
Immune checkpoint inhibitors have been one of the fastest growing classes of medicine in the immuno-oncology field, with close to US$ 50 billion in annual sales Immuno-oncology has grown to almost a rsonal use only Immuno-oncology therapies have had a profound ~US$ 50 billion market impact on the ca
Slide 11: Emergence as an oncology company in an attractive field
Our emergence as an oncology company places us in an attractive field where we have the potential to succeed Oncology is one of the fastest Oncology products receive focus Oncology favours smaller companies with >50% of product rsonal use only growing market segments in the from regulators, with hig
Slide 12: A highly skilled Board and Senior Management Team
Percheron has a highly skilled Board and Senior Management Team Board of Directors Dr Charmaine Dr Michael Dr Gil Dr James rsonal use only Gittleson Baker Price Garner NON-EXECUTIVE CHAIR CHIEF EXECUTIVE OFFICER NON-EXECUTIVE DIRECTOR NON-EXECUTIVE OF THE BOARD & MANAGING DIRECTOR & CHAIR OF AUDIT D
Slide 13: Contact Us
rsonal use only Contact Us L30, Collins Place 35 Collins Street Melbourne, VIC 3000 Australia +61 3 9827 8999 info@PercheronTx.com ASX: PER US OTC: PERCF WWW.PERCHERONTX.COM
Percheron Therapeutics — Shareholder Meeting (October 2026) on 6ix